Medivir AB - TMC435 Will be Evaluated in a Phase II Combination Study With Daclatasvir (BMS 790052) for HCV Genotype-1 Patients

Published: Dec 02, 2011

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY).

Back to news